News Briefs

Anthem, Inc. will acquire myNEXUS, Inc., “a comprehensive home-based nursing management company,” the insurer said on March 24. The provider-facing myNEXUS platform facilitates authorization by a payer for home nursing services. “Bringing the right level of whole person care into the home has been demonstrated to improve outcomes, reduce readmissions and improve members’ and their family’s experience of wellbeing,” said Prakash Patel, M.D., Anthem executive vice president, and president of its Diversified Business Group. myNEXUS currently serves 1.7 million Medicare Advantage members across 20 states, according to the release, and “combines an advanced analytic rules engine, with a clinical staff of over 250 clinicians to effectively plan for and to optimize home care” and “has established a nationwide network of high performing home health providers and nurse agencies.” Read more at https://bit.ly/3cmWjAK.

The Biden administration has extended the pandemic-driven special enrollment period (SEP) on HealthCare.gov through Aug. 15. The SEP started on Feb. 15, and previously was slated to end on May 15. The extension will allow enrollees to take advantage of expanded tax credits now offered as part of recently passed COVID-19 relief legislation — including people currently enrolled in exchange plans, who will have the opportunity to choose a new plan with an updated price. Research by the Kaiser Family Foundation found that “the number of people eligible for a subsidy to purchase Marketplace coverage has increased 20% from 18.1 million to 21.8 million” after passage of the pandemic relief bill. Learn more at https://go.cms.gov/31l6xvq and https://bit.ly/2NTkA8d.

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

needle-and-bills
September 6

Health Care Utilization Outpaces Pre-Pandemic Levels in Early 2024

READ MORE
happy-guys-on-computer
September 6

CareFirst’s Involvement in Startup Accelerator Shows its Intrigue With AI

READ MORE
cigna-on-laptop
September 6

Cigna CEO Offers Medical Cost Update, Touts Stelara Biosimilar

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today